Tokai Pharmaceuticals Obtains $35,500,000 Series E Round

  • Feed Type
  • Date
    5/15/2013
  • Company Name
    Tokai Pharmaceuticals
  • Mailing Address
    One Broadway 14th Floor Cambridge , MA 02142
  • Company Description
    The company develops biopharmaceutical products that focus on endocrine treatment.
  • Website
    http://www.tokaipharmaceuticals.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $35,500,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    The proceeds will be used to expand the ongoing ARMOR2 Phase 2 clinical trial of galeterone in patients with castration-resistant prostate cancer (CRPC) and prepare for registration studies.
  • M&A Terms
  • Venture Investor
    Apple Tree Partners
  • Venture Investor
    Novartis Venture Fund
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.